Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$47.32 USD
-1.61 (-3.29%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $47.38 +0.06 (0.13%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Twist Bioscience (TWST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$45.56 | $65.00 | $28.00 | -6.89% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Twist Bioscience comes to $45.56. The forecasts range from a low of $28.00 to a high of $65.00. The average price target represents a decline of 6.89% from the last closing price of $48.93.
Analyst Price Targets (9 )
Broker Rating
Twist Bioscience currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, eight are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TWST.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.60 | 1.60 | 1.60 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/4/2024 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
5/7/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
5/3/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
5/3/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
5/3/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
4/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steven Mah | Strong Buy | Strong Buy |
2/2/2024 | SVB Securities | Puneet Souda | Hold | Hold |
1/18/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $45.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | -0.79 |